SoftBank-Backed Genetic Testing Invitae's Descent From $7B Valuation to Near-Bankruptcy
SoftBank-Backed Genetic Testing Invitae's Descent From $7B Valuation to Near-Bankruptcy
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks.
据报道，由软银集团（场外交易代码：SFTBY）（场外交易代码：SFTBF）支持的Invitae公司（纽约证券交易所代码：NVTA）将在未来几周内处于申请破产的边缘。
The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges.
这家总部位于旧金山的医学遗传学公司正在努力应对15亿美元的巨额债务负担，正在寻求FTI Consulting的重组顾问和Kirkland & Ellis的法律顾问的专业知识来应对其财务挑战。
Amidst this financial turmoil, Invitae is actively exploring various strategic options, and bankruptcy is a prominent consideration.
在这场金融动荡中，Invitae正在积极探索各种战略选择，破产是一个重要的考虑因素。
The company, known for its aggressive acquisition approach in recent years, has initiated the shedding of assets and cost-cutting measures to address its precarious financial situation, the Wall Street Journal noted.
《华尔街日报》指出，该公司近年来以其激进的收购方针而闻名，已开始削减资产和削减成本的措施，以解决其不稳定的财务状况。
Notably, the downward trajectory of Invitae mirrors the struggles faced by its industry counterpart, 23andMe Holdings Co (NASDAQ:ME), a genetic testing company.
值得注意的是，Invitae的下行轨迹反映了其行业同行、基因检测公司23andMe Holdings Co（纳斯达克股票代码：ME）所面临的困境。
23andMe's market cap plummeted from $6 billion in 2021 to a mere $332 million, reflecting the challenges within the genetic testing sector.
23andMe的市值从2021年的60亿美元暴跌至仅3.32亿美元，这反映了基因检测领域的挑战。
Invitae's stock, which once soared above $50, dramatically declined. The company's market cap, previously exceeding $7 billion, has dwindled significantly over the past 12 months, experiencing an 82% loss in value.
Invitae的股票曾飙升至50美元以上，但大幅下跌。该公司的市值此前已超过70亿美元，在过去12个月中大幅下降，市值损失了82％。
Having invested $1.2 billion in convertible debt in 2021 to support Invitae's asset acquisition plans, SoftBank remains a stakeholder in the beleaguered company.
软银在2021年投资了12亿美元的可转换债券，以支持Invitae的资产收购计划，但它仍然是这家陷入困境的公司的利益相关者。
In January, Invitae sold its non-invasive prenatal and carrier screening business to Natera Inc (NASDAQ:NTRA) for $10 million. The transaction includes $42.5 million in potential milestone payments, including cash and litigation-related credits.
1月，Invitae以1000万美元的价格将其非侵入性产前和携带者筛查业务出售给了Natera Inc（纳斯达克股票代码：NTRA）。该交易包括4,250万美元的潜在里程碑付款，包括现金和诉讼相关信贷。
In December 2023, Invitae divested Ciitizen's assets and announced strategic cost cuts, including workforce reduction and other operating expense reductions, with an anticipated cash savings of approximately $90 million-100 million on an annualized basis.
2023年12月，Invitae剥离了Ciitizen的资产，并宣布了战略成本削减，包括裁员和其他运营费用削减，预计按年计算可节省约9000万至1亿美元的现金。
Price Action: NVTA shares are down 68.80% at $0.122 on the last check Monday.
价格走势：周一的最后一次支票中，NVTA股价下跌68.80％，至0.122美元。
Photo via Wikimedia Commons
照片来自维基共享资源